


Please amend claims 1, 2, 8, 9, 16, 17, 22, 44, 46 and 47.


In the claims

1. (currently amended) A compound of formula (1)



wherein

the group R_1-A is a purine radical of formula (2)



X is oxygen;

R_1 is a group $-R_2-L_2$ ~~or a group $-R_5$~~ ;

R_2 and R_4 are, independently of each other, a straight or branched chain alkylene group or polyvalent branched chain alkyl group with 1 to 300 carbon atoms, optionally substituted by a lower alkyl, lower alkoxy, lower acyloxy or halogen wherein optionally

(a) one or more carbon atoms are replaced by oxygen;

(b) one or more carbon atoms are replaced by nitrogen carrying a hydrogen atom, and the adjacent carbon atom is substituted by oxo;

(c) one or more carbon atoms are replaced by oxygen, and the adjacent carbon atom is substituted by oxo;

(d) the bond between two adjacent carbon atoms is a double or a triple bond;

(e) one or more carbon atoms are replaced by a phenylene, a saturated or unsaturated cycloalkylene, a saturated or unsaturated bicycloalkylene, a bridging divalent heteroaromatic or a bridging divalent saturated or unsaturated heterocyclyl group;

(f) two adjacent carbon atoms are replaced by a disulfide linkage;

or a combination of two or more alkylene and/or modified alkylene groups as defined under (a) to (f) ~~above hereinbefore,~~
~~optionally containing substituents;~~

R₃ is an aromatic or a heteroaromatic group, or an optionally substituted 1-alkenylene, 1-alkynylene, 1-cycloalkenylene, or an unsaturated heterocyclyl group with the double bond connected to CH₂;

~~R₅ is an optionally substituted cycloalkyl, cycloalkenyl or heterocyclyl group;~~

R₆ is hydrogen, hydroxy or unsubstituted or substituted amino; one of R₇ ~~and~~ or R₈ is R₁ and the other one is hydrogen; and

L₁ and L₂ are ~~one or a plurality of~~ the same or different labels and each is selected from the group consisting of a spectroscopic probe fluorophore or a chromophore, a magnetic probe, a contrast reagent, a radioactive moiety, avidin, streptavidin, biotin, a moiety which is capable of crosslinking to other molecules selected from the ~~group consisting of~~ a maleimide, an activated carboxy group ~~active ester~~, an azide and a benzophenone; a tethered metal-chelate which is capable of generating hydroxyl radicals upon exposure to H₂O₂, ~~and~~ ascorbate, malachite green, a moiety covalently attached to a solid support, a lipid, methotrexate, a linear poly(arginine) of D- and/or L-arginine

with 6-15 arginine residues, a linear polymer of 6-15 subunits each carrying a guanidinium group, oligomers or short length polymers of 6-50 subunits wherein at least one subunit has an attached guanidine group a portion of which have attached guanidinium groups, or a peptide having an RKRRQRRR amino acid sequence (SEQ ID NO:1) and parts of a sequence of HIV-tat protein; or

L_1 is a bond connecting R_4 to A forming a cyclic substrate; a further group $-R_3-CH_2-X-A-R_{1-7}$ or a nucleic acid or a derivative thereof capable of undergoing base-pairing with its complementary strand; or L_2 is a nucleic acid or a derivative thereof capable of undergoing base-pairing with its complementary strand if R_7 is hydrogen.

2. (currently amended) The compound according to claim 1, wherein R_3 is phenylene, an unsubstituted or substituted mono- or bicyclic bridging divalent heteroaryl group of 5 or 6 rings atoms comprising zero, one, two, three or four ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, with the proviso that at least one ring carbon atom is replaced by a nitrogen, oxygen or sulfur atom, 1-alkenylene, 1-alkynylene, 1-cyclohexenylene with 3 to 7 carbon atoms, wherein the double or triple bond is connected to CH_2 , or an optionally substituted unsaturated bridging divalent heterocyclyl group with 3 to 12 atoms and 1 to 5 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and a double bond in the position connecting the heterocyclyl group to CH_2 ; and R_5 is optionally substituted cycloalkyl with 3 to 7 carbon atoms; optionally substituted cycloalkenyl with 5 to 7 carbon atoms; or optionally substituted saturated or unsaturated heterocyclyl with 3 to 12 atoms, and 1 to 5 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur tetrahydrofuranyl optionally substituted by hydroxy or hydroxy lower alkyl.

3. (cancelled)
4. (previously presented) The compound according to claim 1, wherein R₃ is phenylene.
5. (previously presented) The compound according to claim 1, wherein R₃ is thienylene.
6. (previously presented) The compound according to claim 1, wherein R₆ is unsubstituted amino, R₇ is R₁, and R₈ is hydrogen.
7. (previously presented) The compound according to claim 1, wherein R₆ is unsubstituted amino, R₇ is a group -R₂-L₂, and R₈ is hydrogen.
8. (currently amended) The compound according to claim 7, wherein L₂ is a ~~spectroscopic probe~~ fluorophore or a chromophore.
9. (currently amended) The compound according to claim 7, wherein ~~L₁ and L₂ are spectroscopic probes~~ is a fluorophore or a chromophore and L₂ is a fluorophore or a chromophore.
10. (currently amended) The compound according to claim 9, wherein each of L₁ and L₂ represents a fluorescence donor or fluorescence quencher pair.
11. (currently amended) The compound according to claim 10, wherein L₁ and L₂ ~~represent~~ constitute a FRET pair.

12-13. (cancelled)

14. (previously presented) The compound according to claim 1, wherein R₆ is unsubstituted amino, R₇ is hydrogen, and R₈ is R₁.

15. (previously presented) The compound according to claim 1, wherein R₆ is unsubstituted amino, R₇ is hydrogen, and R₈ is a group - R₂-L₂.

16. (currently amended) The compound according to claim 15, wherein L₂ is a ~~spectroscopic probe~~ fluorophore or a chromophore.

17. (currently amended) The compound according to claim ~~15~~ 16, wherein L₁ ~~and L₂ are spectroscopic probes~~ is a fluorophore or a chromophore.

18. (currently amended) The compound according to claim 17, wherein L₁ and L₂ ~~represent~~ constitute a fluorescence donor ~~or a~~ fluorescence quencher ~~pair~~.

19. (currently amended) The compound according to claim 18, wherein L₁ and L₂ ~~represent~~ constitute a donor or an acceptor in a FRET pair.

20. (previously presented) The compound according to claim 15, wherein L₂ is avidin, streptavidin or biotin.

21. (previously presented) The compound according to claim 15, wherein L₂ is a moiety covalently attached to a solid support.

22. (currently amended) The compound according to claim 15, wherein L₂ is a linear poly(arginine) of D- and/or L-arginine with 6-15 arginine residues, an oligomer of 6-50 subunits wherein at least one subunit has an attached guanidine group or a peptide having an RKKRRQRRR amino acid sequence (SEQ ID NO:1) a linear polymer of 6-15 subunits each carrying a guanidinium group, oligomers or short-length polymers of 6-50 subunits, a portion of which have attached guanidinium groups, or parts of a sequence of HIV-tat-protein.

23-43 (cancelled)

44. (currently amended) A method for detecting ~~and/or manipulating~~ a protein of interest, wherein the protein of interest is fused to an mutant of a human AGT, the method comprising:

(a) contacting the AGT fusion protein ~~is contacted~~ with a compound of formula (1) according to claim 1; and;

(b) detecting the AGT fusion protein ~~is detected and optionally further manipulated~~ using the label L₁ and/or L₂ in a system designed for recognizing and/or handling the label.

45. (currently amended) The method according to claim 44, wherein in the compound of formula (1) ~~label~~ L₂ is a solid support, and the AGT fusion protein contacted with the compound of formula (1) is separated from the compound of formula (1) by filtration or centrifugation or separation of magnetic beads.

46. (currently amended) The method according to claim 44, wherein in the compound of formula (1) ~~label~~ L₁ is one member and ~~label~~ L₂ the other member of two interacting ~~spectroscopic probes~~ chromophores or fluorophores L₁-L₂, wherein energy can be

transferred nonradiatively through dynamic or static quenching, and the AGT fusion protein is detected by fluorescence.

47. (currently amended) The method according to claim 44 for detecting ~~and/or manipulating~~ a protein of interest, wherein the protein of interest is fused with a mutant of a human AGT, comprising:

(a) ~~contacting~~ the mutant of the human AGT fusion protein is ~~contacted~~ with a mixture of

(i)a) a compound of formula (1) wherein ~~R₁ is a group~~ additionally comprises R₅, wherein R₅ is a substituted or unsubstituted cycloalkyl, cycloalkenyl or heterocyclyl group ~~and~~ which does not react with the mutant AGT₁ and₇

(ii)b) another compound of formula (1), which reacts with the mutant AGT fusion protein₁ and₇

(b) ~~detecting~~ the mutant AGT fusion protein ~~is detected and optionally further manipulated~~ using the label in a system designed for recognizing and/or handling the label.